The Lancet. Oncology

Keyphrases

Publications

volume 25, number 8, 2024

Delphine Borchiellini, Karim Bensalah
Perioperative immunotherapy in renal cell carcinoma. The Lancet. Oncology 25 (8) (2024)
Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman, Suzanne M Cole, Charles G Drake, Sabina Signoretti, Mahmut Akgul, Nicholas Baniak, Elsa Li-Ning, Matthew B Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Kaimakliotis, Yasser Ged, Phillip M Pierorazio, E Jason Abel, Mehmet A Bilen, Kenneth Ogan, Helen H Moon, Krishna A Ramaswamy, Eric A Singer, Tina M Mayer, Jay Lohrey, Vitaly Margulis, Jessie Gills, Scott E Delacroix, Mark J Waples, Andrew C James, Peng Wang, Toni Choueiri, M Dror Michaelson, Anil Kapoor, Daniel Y Heng, Brian Shuch, Bradley C Leibovich, Primo N Lara, Judith Manola, Deborah Maskens, Dena Battle, Robert Uzzo, Gennady Bratslavsky, Naomi B Haas, Michael A Carducci
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. The Lancet. Oncology 25 (8) (2024)
Emma Wilkinson
Cancer priorities set out in manifestos as organisations warn of worsening standards. The Lancet. Oncology 25 (8) (2024)
Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Sonja Zweegman, Hélène Caillon, Denis Caillot, Hervé Avet-Loiseau, Michel Delforge, Thomas Dejoie, Thierry Facon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon-Siong Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Jean Marc Schiano de Colella, Niels Wcj van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean-Pierre Marolleau, Nathalie Meuleman, Marie-Christiane Vekemans, Matthijs Westerman, Saskia K Klein, Mark-David Levin, Fritz Offner, Martine Escoffre-Barbe, Jean-Richard Eveillard, Réda Garidi, Winnie Hua, Jianping Wang, Alba Tuozzo, Carla de Boer, Melissa Rowe, Veronique Vanquickelberghe, Robin Carson, Jessica Vermeulen, Jill Corre, Pieter Sonneveld, null null
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. The Lancet. Oncology 25 (8) (2024)
Ranjeet Bajpai, Jyoti Bajpai
Closing the research gaps in obstetric health for survivors of cancer. The Lancet. Oncology 25 (8) (2024)
Meral Beksac
Daratumumab maintenance in patients with myeloma. The Lancet. Oncology 25 (8) (2024)
Anna Dowrick, Sue Ziebland, Tanvi Rai, Claire Friedemann Smith, Brian D Nicholson
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care. The Lancet. Oncology 25 (8) (2024)
Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman, Suzanne M Cole, Charles G Drake, Sabina Signoretti, Mahmut Akgul, Nicholas Baniak, Elsa Li-Ning, Matthew B Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Kaimakliotis, Yasser Ged, Phillip M Pierorazio, E Jason Abel, Mehmet A Bilen, Kenneth Ogan, Helen H Moon, Krishna A Ramaswamy, Eric A Singer, Tina M Mayer, Jay Lohrey, Vitaly Margulis, Jessie Gills, Scott E Delacroix, Mark J Waples, Andrew C James, Peng Wang, Toni Choueiri, M Dror Michaelson, Anil Kapoor, Daniel Y Heng, Brian Shuch, Bradley C Leibovich, Primo N Lara, Judith Manola, Deborah Maskens, Dena Battle, Robert Uzzo, Gennady Bratslavsky, Naomi B Haas, Michael A Carducci
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. The Lancet. Oncology 25 (8) (2024)
Shilpa S Murthy, Dario Trapani, Bochen Cao, Freddie Bray, Shashanka Murthy, Thomas Peter Kingham, Chandrakanth Are, André M Ilbawi
Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000-19: a retrospective, cross-sectional, population-based study. The Lancet. Oncology 25 (8) (2024)
Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman, Suzanne M Cole, Charles G Drake, Sabina Signoretti, Mahmut Akgul, Nicholas Baniak, Elsa Li-Ning, Matthew B Palmer, Hamid Emamekhoo, Nabil Adra, Hristos Kaimakliotis, Yasser Ged, Phillip M Pierorazio, E Jason Abel, Mehmet A Bilen, Kenneth Ogan, Helen H Moon, Krishna A Ramaswamy, Eric A Singer, Tina M Mayer, Jay Lohrey, Vitaly Margulis, Jessie Gills, Scott E Delacroix, Mark J Waples, Andrew C James, Peng Wang, Toni Choueiri, M Dror Michaelson, Anil Kapoor, Daniel Y Heng, Brian Shuch, Bradley C Leibovich, Primo N Lara, Judith Manola, Deborah Maskens, Dena Battle, Robert Uzzo, Gennady Bratslavsky, Naomi B Haas, Michael A Carducci
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. The Lancet. Oncology 25 (8) (2024)
Ceren Sunguc, David L Winter, Emma J Heymer, Gavin Rudge, Angela Polanco, Katherine A Birchenall, Melanie Griffin, Richard A Anderson, W Hamish B Wallace, Michael M Hawkins, Raoul C Reulen
Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study. The Lancet. Oncology 25 (8) (2024)
Leslie T Stayner, Tania Carreón-Valencia, Paul A Demers, Jason M Fritz, Malcolm R Sim, Patricia Stewart, Hiroyuki Tsuda, Andres Cardenas, Dario Consonni, Laurie Davies, Sara De Matteis, Emanuela Felley-Bosco, Andrew J Ghio, Thomas Göen, Yann Grosse, Alessandro F Gualtieri, P David Josephy, Stella Koutros, Igor Linhart, Henriqueta Louro, Katie M O'Brien, Simona Panzacchi, Laura Peña, Pavel Rössner, Joellen M Schildkraut, Aleksandr B Stefaniak, Nicolas Wentzensen, Pascal Wild, Yuanyuan Xu, Aline de Conti, Caterina Facchin, Roland Wedekind, Ayat Ahmadi, Jessica Blanco, Shirisha Chittiboyina, Shalini Kulasingam, Richard MacLehose, Melitah Motlhale, Sanam Shah, Eero Suonio, Heidi Mattock, Andrew Kunzmann, Federica Madia, Elisa Pasqual, Lamia Benbrahim-Tallaa, Mary K Schubauer-Berigan
Carcinogenicity of talc and acrylonitrile. The Lancet. Oncology 25 (8) (2024)
Shilpa S Murthy, Dario Trapani, Bochen Cao, Freddie Bray, Shashanka Murthy, Thomas Peter Kingham, Chandrakanth Are, André M Ilbawi
Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000-19: a retrospective, cross-sectional, population-based study. The Lancet. Oncology 25 (8) (2024)
Guihong Wan, Wenxin Chen, Sara Khattab, Katie Roster, Nga Nguyen, Boshen Yan, Ahmad Rajeh, Jayhyun Seo, Hannah Rashdan, Leyre Zubiri, Matthew J Hadfield, Shadmehr Demehri, Kun-Hsing Yu, William Lotter, Alexander Gusev, Nicole R LeBoeuf, Kerry L Reynolds, Shawn G Kwatra, Yevgeniy R Semenov
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. The Lancet. Oncology 25 (8) (2024)

volume 25, number 9, 2024

Carien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, Emma Allanson, Lauriane Eberst, Se Ik Kim, Remi A Nout, Jeong-Yeol Park, Domenica Lorusso, Linda Mileshkin, Petronella B Ottevanger, Alison Brand, Delia Mezzanzanica, Amit Oza, Val Gebski, Bhavana Pothuri, Tania Batley, Carol Gordon, Tina Mitra, Helen White, Brooke Howitt, Xavier Matias-Guiu, Isabelle Ray-Coquard, David Gaffney, William Small, Austin Miller, Nicole Concin, Matthew A Powell, Gavin Stuart, Michael A Bookman, null null
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup. The Lancet. Oncology 25 (9) (2024)
Pierre Vera, Sébastien Thureau, Florence Le Tinier, Philippe Chaumet-Riffaud, Sébastien Hapdey, Hélène Kolesnikov-Gauthier, Etienne Martin, Alina Berriolo-Riedinger, Nicolas Pourel, Jean Marc Broglia, Pierre Boissellier, Sophie Guillemard, Naji Salem, Isabelle Brenot-Rossi, Cécile Le Péchoux, Céline Berthold, Etienne Giroux-Leprieur, Damien Moreau, Sophie Guillerm, Khadija Benali, Laurent Tessonnier, Clarisse Audigier-Valette, Delphine Lerouge, Elske Quak, Carole Massabeau, Frédéric Courbon, Patricia Moisson, Anne Larrouy, Romain Modzelewski, Pierrick Gouel, Nadia Ghazzar, Alexandra Langlais, Elodie Amour, Gérard Zalcman, Philippe Giraud
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [ 18 F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial. The Lancet. Oncology 25 (9) (2024)
Brent O'Carrigan, Pippa G Corrie
Measuring success of adjuvant treatment for patients with melanoma. The Lancet. Oncology 25 (9) (2024)
Emanuel Bührer, Michal Kicinski, Mario Mandala, Madeline Pe, Georgina V Long, Victoria Atkinson, Christian U Blank, Andrew Haydon, Stéphane Dalle, Adnan Khattak, Matteo S Carlino, Andrey Meshcheryakov, Shahneen Sandhu, Susana Puig, Dirk Schadendorf, Rahima Jamal, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Corneel Coens, Dmitri Grebennik, Clemens Krepler, Caroline Robert, Alexander M M Eggermont
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology 25 (9) (2024)
Jeanine M L Roodhart, Miriam Koopman
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more? The Lancet. Oncology 25 (9) (2024)
Nathalie L Albert, Emilie Le Rhun, Giuseppe Minniti, Maximilian J Mair, Norbert Galldiks, Nelleke Tolboom, Asgeir S Jakola, Maximilian Niyazi, Marion Smits, Antoine Verger, Francesco Cicone, Michael Weller, Matthias Preusser, null null
Translating the theranostic concept to neuro-oncology: disrupting barriers. The Lancet. Oncology 25 (9) (2024)
Xiang Li, Guo-Bao Huang
Enhancing equity and long-term impact assessments in radiotherapy environmental studies. The Lancet. Oncology 25 (9) (2024)
Mafalda Oliveira, Hope S Rugo, Sacha J Howell, Florence Dalenc, Javier Cortes, Henry L Gomez, Xichun Hu, Masakazu Toi, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Zbigniew Nowecki, Yeon Hee Park, Joo Hyuk Sohn, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Marta Fulford, Haylee Andrews, Ian Wadsworth, Celina D'Cruz, Nicholas C Turner, null null
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology 25 (9) (2024)
Andrea V Barrio
Time to abandon axillary lymph node dissection in early-stage breast cancer. The Lancet. Oncology 25 (9) (2024)
Jana de Boniface, Matilda Appelgren, Robert Szulkin, Sara Alkner, Yvette Andersson, Leif Bergkvist, Jan Frisell, Oreste Davide Gentilini, Michalis Kontos, Thorsten Kühn, Dan Lundstedt, Birgitte Vrou Offersen, Roger Olofsson Bagge, Toralf Reimer, Malin Sund, Peer Christiansen, Lisa Rydén, Tove Filtenborg Tvedskov, null null
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. The Lancet. Oncology 25 (9) (2024)
Guang Yang, Jun Dou
Enhancing equity and long-term impact assessments in radiotherapy environmental studies. The Lancet. Oncology 25 (9) (2024)
Madeleine J Karpinski, Johannes Hüsing, Kevin Claassen, Lennart Möller, Hiltraud Kajüter, Florian Oesterling, Viktor Grünwald, Lale Umutlu, Jens Kleesiek, Tugce Telli, Anja Merkel-Jens, Anika Hüsing, Claudia Kesch, Ken Herrmann, Matthias Eiber, Sebastian Hoberück, Philipp T Meyer, Felix Kind, Kambiz Rahbar, Michael Schäfers, Andreas Stang, Boris A Hadaschik, Wolfgang P Fendler
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. The Lancet. Oncology 25 (9) (2024)
Talha Burki
Peru advances towards universal health care for patients with cancer. The Lancet. Oncology 25 (9) (2024)
Magali Svrcek, Thibault Voron, Thierry André, Elizabeth C Smyth, Christelle de la Fouchardière
Improving individualised therapies in localised gastro-oesophageal adenocarcinoma. The Lancet. Oncology 25 (9) (2024)
Wiaam Elkhatib, Prajwal Reddy
Multimodality imaging of a large incidental papillary fibroelastoma. The Lancet. Oncology 25 (9) (2024)
Ghada Zakout
Contextualising legal and ethical conundrums of artificial intelligence in oncology. The Lancet. Oncology 25 (9) (2024)
Fei Liu, Qing Lan, Long Guo
Enhancing cardiovascular disease risk management in childhood cancer survivors. The Lancet. Oncology 25 (9) (2024)
Mark Lawler, Grazia Scocca, Françoise Meunier
Ending financial discrimination for cancer survivors: embedding the Right to be Forgotten in legislation across Europe. The Lancet. Oncology 25 (9) (2024)
Lan Yang, Jinlong Jiang, Shijie Guo
Enhancing cardiovascular disease risk management in childhood cancer survivors. The Lancet. Oncology 25 (9) (2024)
Hans-Christian Kolberg, Cornelia Kolberg-Liedtke
Who does not benefit from whole-breast radiotherapy and how to find them? The Lancet. Oncology 25 (9) (2024)
Zachary J Ward, Qassi Gaba, Rifat Atun
Cancer incidence and survival for 11 cancers in the Commonwealth: a simulation-based modelling study. The Lancet. Oncology 25 (9) (2024)
Kanwal Raghav, Salvatore Siena, Atsuo Takashima, Takeshi Kato, Marc Van den Eynde, Filippo Pietrantonio, Yoshito Komatsu, Hisato Kawakami, Marc Peeters, Thierry Andre, Sara Lonardi, Kensei Yamaguchi, Jeanne Tie, Cristina Gravalos Castro, Hung-Chih Hsu, John H Strickler, Tae-You Kim, Yongjun Cha, Daniel Barrios, Qi Yan, Takahiro Kamio, Kojiro Kobayashi, Aislyn Boran, Makito Koga, John D Allard, Takayuki Yoshino
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. The Lancet. Oncology 25 (9) (2024)
Jean-Yves Blay, Quentin Devin, Florence Duffaud, Maud Toulmonde, Nelly Firmin, Olivier Collard, Emmanuelle Bompas, Benjamin Verret, Isabelle Ray-Coquard, Sebastien Salas, Clemence Henon, Charles Honoré, Mehdi Brahmi, Armelle Dufresne, Marc Pracht, Alice Hervieu, Nicolas Penel, Francois Bertucci, Maria Rios, Esma Saada-Bouzid, Pauline Soibinet, David Perol, Sylvie Chabaud, Antoine Italiano, Axel Le Cesne
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology 25 (9) (2024)
Karl Gruber
New immigration laws could undermine cancer research in the UK. The Lancet. Oncology 25 (9) (2024)
Talha Burki
Poor progress on reducing alcohol consumption in Europe. The Lancet. Oncology 25 (9) (2024)
null The Lancet Oncology
Legacies of conflict and humanitarian crises on cancer care. The Lancet. Oncology 25 (9) (2024)
Karl Gruber
Improving cancer control initiatives in Indigenous people. The Lancet. Oncology 25 (9) (2024)
Camilo E Fadul, Jason P Sheehan, Julio Silvestre, Gloribel Bonilla, Joseph A Bovi, Manmeet Ahluwalia, Riccardo Soffietti, David Hui, Roger T Anderson
Defining the quality of interdisciplinary care for patients with brain metastases: modified Delphi panel recommendations. The Lancet. Oncology 25 (9) (2024)
Sharmila Devi
Progress in NCD screening in Mongolia. The Lancet. Oncology 25 (9) (2024)
Philipp Karschnia, Jasper K W Gerritsen, Nico Teske, Daniel P Cahill, Asgeir S Jakola, Martin van den Bent, Michael Weller, Oliver Schnell, Einar O Vik-Mo, Niklas Thon, Arnaud J P E Vincent, Michelle M Kim, Guido Reifenberger, Susan M Chang, Shawn L Hervey-Jumper, Mitchel S Berger, Joerg-Christian Tonn
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group. The Lancet. Oncology 25 (9) (2024)
Linda J Williams, Ian H Kunkler, Karen J Taylor, Joanna Dunlop, Tammy Piper, Jacqueline Caldwell, Wilma Jack, Joseph F Loane, Kenneth Elder, John M S Bartlett, J Michael Dixon, David A Cameron
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial. The Lancet. Oncology 25 (9) (2024)
Ryan A Denu, Neeta Somaiah
Imatinib in advanced GIST: if it's working, don't stop a good thing. The Lancet. Oncology 25 (9) (2024)
Elizabeth Gourd
Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS. The Lancet. Oncology 25 (9) (2024)
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, Francesca Galli, Emma Hudson, Yoland Antill, Chel Hun Choi, Manuela Rabaglio, Frederic Marmé, Christian Marth, Gabriella Parma, Lorena Fariñas-Madrid, Shin Nishio, Karen Allan, Yeh Chen Lee, Elisa Piovano, Beatriz Pardo, Satoshi Nakagawa, John McQueen, Claudio Zamagni, Luis Manso, Kazuhiro Takehara, Giulia Tasca, Annamaria Ferrero, Germana Tognon, Andrea Alberto Lissoni, Mariacristina Petrella, Maria Elena Laudani, Eliana Rulli, Sara Uggeri, M Pilar Barretina Ginesta, null null
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology 25 (9) (2024)
Kirsten Bouchelouche, Peter L Choyke
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer. The Lancet. Oncology 25 (9) (2024)
Paul Adepoju
Over US$100 million pledged to improve cancer care across Africa. The Lancet. Oncology 25 (9) (2024)